VACCINE FOR PATIENTS WITH NON HODGKINS LYMPHOMA

非霍奇金淋巴瘤患者的疫苗

基本信息

批准号：
6377999
负责人：
Asher A Chanan-Khan
金额：
$ 15.99万
依托单位：
ROSWELL PARK CANCER INSTITUTE CORP
依托单位国家：
美国
项目类别：
财政年份：
2000
资助国家：
美国
起止时间：
2000-09-18 至 2003-09-01
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/6377999
关键词：
clinical research cytotoxic T lymphocyte delayed hypersensitivity dendritic cells enzyme linked immunosorbent assay human subject human therapy evaluation interferon gamma lymphocyte monocyte neoplasm /cancer immunotherapy neoplasm /cancer vaccine nonHodgkin's lymphoma tumor antigens vaccine development

项目摘要

These investigators propose to clone and sequence the VH regions from lymphoma-associated immunoglobulin from fresh lymph node tissue from patients with recurrent lymphoma. They will chose a peptide sequence of 25-mer from the VH region based on its inclusion of 9 mers having optimal MHC peptide binding capacity using a bio-informatics approach based on predictions using binding motifs established for specific HLA-1 alleles expressed by the patient. The peptide will be synthesized and used to "pulse" dendritic cells enriched from the peripheral blood generated in vivo by treatment with FLT-3 ligand. They anticipate that the multiple antigen presenting cell populations within the DC peripheral blood will process and present a wide spectrum of antigens in the context of MHC class I leading to a broad CD8 + T cell response generated against tumor-associated immunoglobulin, and therefore, the tumor. They anticipate evaluating five patients per year for two years. They will determine the safety and feasibility of the in vivo generation of DC from peripheral blood in this patient population, they will determine the safety and feasibility of vaccination with tumor VH peptide pulsed DC, and determine the clinical and immunologic response of vaccination with the tumor VH peptide pulsed DC from peripheral blood from patients with lymphoma.

这些研究人员建议对 VH 区域进行克隆和测序来自新鲜淋巴结组织的淋巴瘤相关免疫球蛋白复发性淋巴瘤患者。他们将选择 25 聚体的肽序列来自 VH 区，基于其包含具有最佳 MHC 肽的 9 聚体使用生物信息学方法基于预测的结合能力为患者表达的特定 HLA-1 等位基因建立的结合基序。该肽将被合成并用于“脉冲”富集的树突状细胞来自通过FLT-3配体处理在体内产生的外周血。他们预计，体内的多种抗原呈递细胞群 DC外周血将处理并呈递广泛的抗原 MHC I 类背景导致广泛的 CD8 + T 细胞反应对抗肿瘤相关的免疫球蛋白，从而对抗肿瘤。他们预计两年内每年评估五名患者。他们将确定从外周体内产生 DC 的安全性和可行性他们将确定该患者群体的血液的安全性和肿瘤 VH 肽脉冲 DC 疫苗接种的可行性，并确定肿瘤 VH 肽疫苗接种的临床和免疫反应来自淋巴瘤患者外周血的脉冲 DC。